Chemotherapy plus radiotherapy in Clinical Stage IA to IIIB Hodgkin’s disease. Results of the H 77 trial (1977–1980)

  • J. M. Andrieu
  • Y. Coscas
  • P. Cramer
  • C. Julien
  • M. Weil
  • G. Tricot
Part of the Developments in Oncology book series (DION, volume 32)


Major progress in the treatment of Hodgkin’s disease (HD) had been accomplished by the late sixties. Kaplan et al. at Stanford University found that when a very careful staging laparotomy with splenectomy is performed, a majority of patients with Pathologic Stages I and II could be cured by radiotherapy alone [1]. Around the same time, De Vita et al. introduced the MOPP (mechlorethamine, vincristine, procarbazine and prednisone) chemotherapy for the treatment of advanced stages [2]; after 6 cycles of this multiagent chemotherapy, a complete remission was obtained in 60 to 80% of the patients and half of them were probably cured.


Clinical Stage Mediastinal Involvement Staging Laparotomy Splenic Irradiation Total Nodal Irradiation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kaplan HS and Rosenberg SA (1973). Current status of clinical trials: Stanford Experience 1962–1972. Nat Cancer Inst Monogr 36: 363–371.PubMedGoogle Scholar
  2. 2.
    De Vita VT, Serpick AA and Carbone PP (1970). Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med 73: 881–895.Google Scholar
  3. 3.
    Andrieu JM, Montagnon B, Asselain B et al. (1980). Chemotherapy-radiotherapy association for Hodgkin’s disease Stages IA, IIA. Cancer 46: 2126–2130.PubMedCrossRefGoogle Scholar
  4. 4.
    Andrieu JM, Asselain B, Baule C et al. (1981). La séquence polychimiothérapie MOPP irradiation ganglionnaire sélective dans le traitement de la maladie de Hodgkin, Stade clinique IA-IIIB. Résultats à 8 ans d’un protocole prospectif comportant 334 patients. Bull Cancer (Paris) 68: 190–199.Google Scholar
  5. 5.
    Andrieu JM, Casassus P, Coscas Y et al. (1982). Traitement des stades cliniques ganglionnaires intermédiaires et avancés de la maladie de Hodgkin par chimiothérapie courte (3 MOPP ou 3 CVPP)–splénectomie–irradiation limitée. Résultats à 4 ans d’un protocole prospectif (H 7702, 7703) incluant 94 patients. Bull Cancer (Paris) 69: 321–329.Google Scholar
  6. 6.
    Andrieu JM, Ozanne F, Dana M et al. (1981). La séquence polychimiothérapie MOPP-radiothérapie sélective ou focale dans la maladie de Hodgkin, Stades Cliniques IA, II2A. Résultats à 4 ans d’un protocole prospectif (H 7701) incluant 79 patients. Bull Cancer (Paris) 68: 217–223.Google Scholar
  7. 7.
    British National Lymphoma Investigation (1976). Initial treatment of Stage IIIA Hodgkin’s disease. Comparison of radiotherapy with combined chemotherapy. Lancet 2: 991–995.Google Scholar
  8. 8.
    Hoppe RT, Rosenberg SA, Kaplan HS and Cox RS (1980). Prognostic factors in Pathological Stage IIIA Hodgkin’s disease. Cancer 46: 1240–1246.PubMedCrossRefGoogle Scholar
  9. 9.
    Mauch P, Goodmar RL, Rosenthal DS et al. (1979). An evaluation of total nodal irradiation as treatment for Stage III Hodgkin’s disease. Cancer 43: 1255–1261.PubMedCrossRefGoogle Scholar
  10. 10.
    Peckham MJ, Ford HT, McElwain TJ et al. (1975). The results of radiotherapy for Hodgkin’s disease. Br J Cancer 32: 391–400.PubMedCrossRefGoogle Scholar
  11. 11.
    Dolginow D and Colby TV (1981). Recurrent Hodgkin’s disease in treated sites. Cancer 48: 1124–1126.PubMedCrossRefGoogle Scholar
  12. 12.
    Hellman S, Mauch P, Goodman RL et al. (1978). The place of radiation therapy in the treatment of Hodgkin’s disease. Cancer 42: 971–978.PubMedCrossRefGoogle Scholar
  13. 13.
    Lee CK, Bloomfield CD, Godman AI and Levitt SH (1980). Prognostic significance of mediastinal involvement in Hodgkin’s disease treated with curative radiotherapy. Cancer 46: 2403–2409.PubMedCrossRefGoogle Scholar
  14. 14.
    Levi JA, Wiernick PH and O’Connell MJ (1977). Patterns of relapse in Stages I, II and IIIA Hodgkin’s disease: Influence of initial therapy and implications for the future. Int J Radiat Oncol Phys 2: 853–857.CrossRefGoogle Scholar
  15. 15.
    Velentjas E, Barrett A, McElwain TJ and Peckham MJ (1980). Mediastinal involvement in early stage Hodgkin’s disease. Response to treatment and pattern of relapse. Eur J Cancer 16: 1065–1068.PubMedCrossRefGoogle Scholar
  16. 16.
    Rosenberg SA, Kaplan HS, Glatstein EJ and Portlock CS (1978). Combined modality therapy of Hodgkin’s disease. A report on the Stanford trials. Cancer 42: 991–1000.PubMedCrossRefGoogle Scholar
  17. 17.
    Desser RK, Golomb HM, Ultmann JE et al. (1977). Prognostic classification of Hodgkin’s disease in pathological Stage III, based on anatomic considerations. Blood 49: 883–893.PubMedGoogle Scholar
  18. 18.
    Nordentoft AM, Pedersen-Bjergaard J, Brincker H et al. (1980). Hodgkin’s disease in Denmark; A national clinical study by the Danish Hodgkin study group. LYGRA. Scand J Haematol 24: 321–334.CrossRefGoogle Scholar
  19. 19.
    Aisenberg AC, Linggood RM and Lew RA (1979). The changing face of Hodgkin’s disease, Amer J Med 67: 921–928.PubMedCrossRefGoogle Scholar
  20. 20.
    Rutheford CJ, Desforges JF, Davies B et al. (1980). The decision to perform staging laparotomy in symptomatic Hodgkin’s disease. But J Haematol, 44: 347–358.CrossRefGoogle Scholar
  21. 21.
    Aisenberg AC and Quazi R (1974). Abdominal involvement at the onset of Hodgkin’s disease. Amer J Med 57: 850–874.CrossRefGoogle Scholar
  22. 22.
    Andrieu JM, Julien C, Casassus P et al. (1983). MOPP plus irradiation for Hodgkin’s disease CS IA to IIIB, 10 years later. J Clin Oncol 2: 213.Google Scholar
  23. 23.
    Andrieu JM and Ochoa-Molina ME (1983). Menstrual cycle, pregnancies and offspring after MOPP therapy for Hodgkin’s disease. Cancer 52: 435–438.PubMedCrossRefGoogle Scholar
  24. 24.
    Bonadonna G, Zucali R, de Lena M and Valagussa P (1977). Combined chemotherapy ( MOPP or ABVD) — radiotherapy approach in advanced Hodgkin’s disease. Cancer Treat Rep 61: 769–777.PubMedGoogle Scholar
  25. 25.
    Santoro A, Bonadonna G, Zucali R et al. (1981). Therapeutic and toxicologic effects of MOPP versus ABVD when combined with RT in Hodgkin’s disease. Proc Amer Assoc Cancer Res and Amer Soc Clin Oncol 22: 522.Google Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1985

Authors and Affiliations

  • J. M. Andrieu
    • 1
  • Y. Coscas
    • 2
  • P. Cramer
    • 3
  • C. Julien
    • 1
  • M. Weil
    • 4
  • G. Tricot
    • 5
  1. 1.Department of Oncology/hematologyLaennec HospitalParisFrance
  2. 2.Department of RadiotherapySaint-Louis HospitalParisFrance
  3. 3.Department of HematologySaint-Louis HospitalParisFrance
  4. 4.Department of OncologySalpetriere HospitalParisFrance
  5. 5.Department of PathologySaint-Louis HospitalParisFrance

Personalised recommendations